for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BioCryst Pharmaceuticals, Inc.

BCRX.OQ

Latest Trade

2.00USD

Change

0.30(+17.65%)

Volume

693,492

Today's Range

1.78

 - 

2.03

52 Week Range

1.38

 - 

9.94

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

BioCryst Prices Public Offering Of Common Stock

Nov 13 (Reuters) - BioCryst Pharmaceuticals Inc <BCRX.O>::BIOCRYST PRICES PUBLIC OFFERING OF COMMON STOCK.BIOCRYST PHARMACEUTICALS INC- ANNOUNCED PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 37.9 MILLION SHARES, OFFERED AT PRICE OF $1.45 PER SHARE.

BioCryst Commences Public Offering Of Common Stock

Nov 12 (Reuters) - BioCryst Pharmaceuticals Inc <BCRX.O>::BIOCRYST COMMENCES PUBLIC OFFERING OF COMMON STOCK.BIOCRYST PHARMACEUTICALS INC - OFFERING TO SELL $55 MILLION OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.

Biocryst - On Nov 7 Co, Thomas Staab, II, CFO, Mutually Agreed That Staab Will Step Down

Nov 8 (Reuters) - BioCryst Pharmaceuticals Inc <BCRX.O>::BIOCRYST PHARMACEUTICALS - ON NOV 7 CO, THOMAS R. STAAB, II, CFO, MUTUALLY AGREED THAT STAAB WILL STEP DOWN FROM CO EFFECTIVE FEB 29, 2020.BIOCRYST PHARMACEUTICALS INC - THOMAS R. STAAB, II, WILL SERVE AS AN ADVISOR TO COMPANY THROUGH MIDDLE OF 2020 - SEC FILING.BIOCRYST PHARMACEUTICALS INC - WILL ENGAGE IN A SEARCH FOR A NEW CHIEF FINANCIAL OFFICER.

Biocryst Pharmaceuticals Q3 Loss Per Share $0.34

BioCryst Pharmaceuticals Inc <BCRX.O>::BIOCRYST REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND UPCOMING KEY MILESTONES.Q3 LOSS PER SHARE $0.34.Q3 REVENUE $1.8 MILLION VERSUS $1.5 MILLION.Q3 REVENUE ESTIMATE $3 MILLION -- REFINITIV IBES DATA.Q3 EARNINGS PER SHARE ESTIMATE $-0.32 -- REFINITIV IBES DATA.SEES FY2019 NET OPERATING CASH USE $105 TO $130 MILLION.

BioCryst Announces Partnership With Torii Pharmaceutical to Commercialize BCX7353 in Japan for the Prevention of HAE Attacks

Nov 5 (Reuters) - BioCryst Pharmaceuticals Inc <BCRX.O>::BIOCRYST ANNOUNCES PARTNERSHIP WITH TORII PHARMACEUTICAL TO COMMERCIALIZE BCX7353 IN JAPAN FOR THE PREVENTION OF HAE ATTACKS.BIOCRYST PHARMACEUTICALS- WILL RECEIVE $22 MILLION UPFRONT PAYMENT AND IS ELIGIBLE TO RECEIVE UP TO AN ADDITIONAL $20 MILLION UPON ACHIEVEMENT OF CERTAIN MILESTONES.BIOCRYST PHARMACEUTICALS - BIOCRYST WILL RECEIVE TIERED ROYALTIES RANGING FROM MID-TEENS TO POTENTIALLY 40 PERCENT OF JAPANESE NET SALES OF BCX7353.

BioCryst Begins Phase 1 Trial With BCX9250, An Oral ALK-2 Inhibitor, For Treatment Of Fibrodysplasia Ossificans Progressiva

Nov 1 (Reuters) - BioCryst Pharmaceuticals Inc <BCRX.O>::BIOCRYST BEGINS PHASE 1 TRIAL WITH BCX9250, AN ORAL ALK-2 INHIBITOR, FOR TREATMENT OF FIBRODYSPLASIA OSSIFICANS PROGRESSIVA.BIOCRYST PHARMACEUTICALS INC - PHASE 1 DATA EXPECTED IN 2H 2020.BIOCRYST PHARMACEUTICALS INC - PHASE 1 TRIAL WILL EVALUATE SINGLE AND MULTIPLE ASCENDING DOSES OF ORAL BCX9250 IN HEALTHY VOLUNTEERS.

Biocryst Pharmaceuticals Says Co, Subsidiary Entered Into Amendment To Second Amended & Restated Credit & Security Agreement, Dated February 5

Sept 16 (Reuters) - BioCryst Pharmaceuticals Inc <BCRX.O>::BIOCRYST PHARMACEUTICALS INC - CO, SUBSIDIARY ENTERED INTO AMENDMENT TO SECOND AMENDED & RESTATED CREDIT & SECURITY AGREEMENT, DATED FEBRUARY 5.BIOCRYST PHARMACEUTICALS INC - FIRST AMENDMENT TO EXTEND DEADLINE FOR BORROWERS TO DRAW UPON $30 MILLION TRANCHE 2 TO NOVEMBER 30, 2019.BIOCRYST PHARMACEUTICALS - ON SEPT 13, BORROWERS, MIDCAP, AND LENDERS PARTY ENTERED INTO SECOND AMENDMENT TO CREDIT AGREEMENT.BIOCRYST PHARMACEUTICALS INC - SECOND AMENDMENT REVISED DEFINITIONS OF PERMITTED INDEBTEDNESS AND PERMITTED LIENS.BIOCRYST PHARMACEUTICALS - SECOND AMENDMENT TO PERMIT BORROWERS TO INCUR UP TO $1.5 MILLION OF INDEBTEDNESS, FINANCE OF INSURANCE PREMIUMS.

BioCryst Reports Second Quarter 2019 Financial Results

Aug 6 (Reuters) - BioCryst Pharmaceuticals Inc <BCRX.O>::BIOCRYST REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.34.Q2 REVENUE $1.4 MILLION VERSUS $12.5 MILLION.Q2 REVENUE ESTIMATE $2 MILLION -- REFINITIV IBES DATA.Q2 EARNINGS PER SHARE ESTIMATE $-0.31 -- REFINITIV IBES DATA.DATA FROM ONGOING PHASE 1 TRIAL OF ORAL FACTOR D INHIBITOR, BCX9930, EXPECTED IN Q4 2019.BIOCRYST PHARMACEUTICALS - NEW DRUG APPLICATION FOR ONCE-DAILY ORAL BCX7353 FOR PROPHYLAXIS OF HEREDITARY ANGIOEDEMA ATTACKS ON-TRACK FOR SUBMISSION.PLANS TO BEGIN ZENITH-2, A PHASE 3 CLINICAL TRIAL OF ORAL BCX7353 (750 MG) FOR ACUTE TREATMENT OF HAE IN 2020.PREPARING FOR COMMERCIAL LAUNCH OF BCX7353 IN U.S. LATER IN 2020.QTRLY TOTAL REVENUES WERE $1.4 MILLION, COMPARED TO $12.5 MILLION IN Q2 OF 2018.NET LOSS FOR Q2 OF 2019 WAS $37.6 MILLION, OR $0.34 PER SHARE.CASH, CASH EQUIVALENTS AND INVESTMENTS TOTALED $97.5 MILLION AT JUNE 30, 2019.

Biocryst Reports Q1 2019 Results

May 8 (Reuters) - BioCryst Pharmaceuticals Inc <BCRX.O>::BIOCRYST REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.28.Q1 REVENUE $5.9 MILLION VERSUS $4.0 MILLION.Q1 REVENUE ESTIMATE $3.1 MILLION -- REFINITIV IBES DATA.Q1 EARNINGS PER SHARE ESTIMATE $-0.27 -- REFINITIV IBES DATA.BIOCRYST CONTINUES TO EXPECT NET OPERATING CASH USE TO BE IN RANGE OF $105 MILLION TO $130 MILLION FOR 2019.CONTINUES TO EXPECT ITS 2019 OPERATING EXPENSES TO BE IN RANGE OF $120 MILLION TO $145 MILLION.

Biocryst Pharmaceuticals Reports Q4 Loss Per Share Of $0.25

March 4 (Reuters) - BioCryst Pharmaceuticals Inc <BCRX.O>::BIOCRYST REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.25.Q4 REVENUE $2.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $2.8 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $-0.25 -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND INVESTMENTS TOTALED $128.4 MILLION AT DECEMBER 31, 2018.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up